Loxo Oncology

Latest news

• FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers
  26 November 2018
• Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
  21 October 2018
• FDA Accepts Larotrectinib New Drug Application and Grants Priority Review
  29 May 2018
• Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer
  26 March 2018
• Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
  21 February 2018
• Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
  20 December 2017
• Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
  12 December 2017
• Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology
  3 June 2017

Drugs Associated with Loxo Oncology, Inc.

Loxo Oncology, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.